A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.
Jonathan Alexander Chatzkel(University of Florida), Brian Hemendra Ramnaraign(University of Florida Health), Padraic O’Malley(University of Florida), Thomas J. George(University of Florida Health), Wayne Brisbane(University of California, Los Angeles), Carmen J. Allegra(National Cancer Institute), Azka Ali, Ji‐Hyun Lee(Gachon University), Paul L. Crispen(University of Kentucky)
Cited by 0
Related Papers
Sequencing Chromosomal Abnormalities Reveals Neurodevelopmental Loci that Confer Risk across Diagnostic Boundaries
|Cell|2012|598
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
|JNCI Journal of the National Cancer Institute|2011|527
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Preoperative Treatment of Locally Advanced Rectal Cancer
|New England Journal of Medicine|2023|440
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391